In Brief: Biosite Diagnostics/Scios
This article was originally published in The Gray Sheet
Executive Summary
Biosite Diagnostics/Scios: Diagnostic test manufacturer Biosite gains license to utilize biopharmaceutical developer Scios' B-type natriuretic peptide detection technology in its point-of-care congestive heart failure diagnostic. The agreement calls for Biosite to pay licensing fees and product royalties to Scios, terms of which were not disclosed. San Diego-based Biosite also signed an identical deal with biopharmaceutical firm XOMA Corp., giving it access to XOMA's lipopolysaccharide binding protein technology for sepsis detection...